Bristol-Myers and Pfizer to present on diverse topics at ACC
“During ACC, the Bristol-Myers Squibb and Pfizer Alliance will share several analyses that delve deeper into the robust data generated from the ARISTOTLE study,” Dr. Christoph Koenen, vice president and development lead for Eliquis at Bristol-Myers Squibb, said in a statement. “Through continued analyses and support of the ARISTOTLE trial, we can examine topics such as outcomes for patients with different comorbidities and the potential treatment effects of interacting drugs, which expands our scientific understanding.”
The Phase 3 ARISTOTLE trial stands for Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation. The companies will also present on real-world data analyses that showcase their commitment to understanding direct oral anticoagulants in clinical practice.
“As physicians evaluate options for reducing stroke risk in patients with non-valvular atrial fibrillation, they often face questions about the effectiveness and safety of therapies in day-to-day practice,” Dr. Rory O’Connor, chief medical officer for Pfizer Innovative Health, said. “Real-world data analyses allow us to explore the usage of Eliquis and anticoagulants across various geographies and subgroups of patients. Alongside clinical data, the real-world data analyses we are presenting during ACC have the potential to help health care providers make more informed decisions along with their patients.”